We found a significantly shorter OS for the GC patients with high (median OS = 10 months) versus low (median = 34 months) serum sTIE2 (4,428.64pg/mL cut-off value; p < 0.0001) and for high (median OS = 11.5 months) versus low (median = 21 months) serum VEGF-D (1,116.25pg/mL cut-off value; p = 0.027) levels (Fig. 6a, b). The gene discussed is VEGFD; the disease is gastric cancer.